Q1 EPS Estimates for Sage Therapeutics Lifted by Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Sage Therapeutics in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn ($1.17) per share for the quarter, up from their previous estimate of ($1.24). Wedbush currently has a "Neutral" rating and a $6.00 price objective on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics' Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($2.80) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.22) EPS and FY2029 earnings at ($0.90) EPS.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%.

SAGE has been the subject of several other reports. Bank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target for the company. Canaccord Genuity Group lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Wednesday, February 12th. HC Wainwright reissued a "neutral" rating and issued a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Piper Sandler decreased their price target on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, January 2nd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Three investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Sage Therapeutics has a consensus rating of "Hold" and a consensus price target of $8.81.

Sage Therapeutics Stock Performance

NASDAQ:SAGE traded up $0.04 during trading hours on Friday, reaching $7.72. The company's stock had a trading volume of 643,289 shares, compared to its average volume of 1,226,305. The company has a market capitalization of $474.63 million, a P/E ratio of -1.17 and a beta of 0.48. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $14.97. The stock has a 50 day moving average price of $7.49 and a two-hundred day moving average price of $6.73.

Institutional Investors Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Picton Mahoney Asset Management grew its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Sage Therapeutics during the 4th quarter valued at about $49,000. Ieq Capital LLC acquired a new stake in shares of Sage Therapeutics during the fourth quarter worth about $57,000. GAMMA Investing LLC boosted its stake in shares of Sage Therapeutics by 16,118.0% in the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 8,059 shares during the period. Finally, US Bancorp DE grew its holdings in shares of Sage Therapeutics by 22.3% in the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 2,268 shares in the last quarter. 99.22% of the stock is owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.